Zacks Research Issues Negative Estimate for IQVIA Earnings

IQVIA Holdings Inc. (NYSE:IQV - Free Report) - Investment analysts at Zacks Research lowered their Q2 2025 earnings estimates for IQVIA in a research note issued on Tuesday, May 27th. Zacks Research analyst R. Department now anticipates that the medical research company will post earnings of $2.49 per share for the quarter, down from their previous estimate of $2.56. The consensus estimate for IQVIA's current full-year earnings is $10.84 per share. Zacks Research also issued estimates for IQVIA's Q3 2025 earnings at $2.74 EPS, Q4 2025 earnings at $3.04 EPS, FY2025 earnings at $10.64 EPS, Q1 2026 earnings at $2.56 EPS, Q2 2026 earnings at $2.86 EPS, Q3 2026 earnings at $3.11 EPS, Q4 2026 earnings at $3.18 EPS, FY2026 earnings at $11.72 EPS, Q1 2027 earnings at $2.91 EPS and FY2027 earnings at $12.71 EPS.

IQVIA (NYSE:IQV - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The medical research company reported $2.70 EPS for the quarter, beating the consensus estimate of $2.63 by $0.07. The company had revenue of $3.83 billion during the quarter, compared to analysts' expectations of $3.77 billion. IQVIA had a net margin of 8.91% and a return on equity of 28.81%. IQVIA's revenue for the quarter was up 2.5% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.54 earnings per share.

Other equities research analysts have also issued reports about the stock. JPMorgan Chase & Co. dropped their target price on shares of IQVIA from $232.00 to $177.00 and set an "overweight" rating for the company in a research report on Monday, May 19th. Robert W. Baird dropped their target price on shares of IQVIA from $195.00 to $161.00 and set a "neutral" rating for the company in a research report on Wednesday, May 7th. Morgan Stanley boosted their price objective on shares of IQVIA from $245.00 to $250.00 and gave the stock an "overweight" rating in a report on Tuesday, February 11th. Truist Financial lowered their price objective on shares of IQVIA from $263.00 to $216.00 and set a "buy" rating for the company in a report on Thursday, April 10th. Finally, Royal Bank of Canada restated an "outperform" rating and issued a $270.00 price objective on shares of IQVIA in a report on Monday, February 10th. Eight equities research analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $226.32.

IQVIA Price Performance

IQVIA stock traded down $0.86 during mid-day trading on Friday, hitting $140.16. 2,874,682 shares of the company traded hands, compared to its average volume of 1,570,084. IQVIA has a one year low of $134.65 and a one year high of $252.88. The stock has a market cap of $24.25 billion, a price-to-earnings ratio of 18.69, a price-to-earnings-growth ratio of 1.99 and a beta of 1.34. The company has a debt-to-equity ratio of 2.12, a quick ratio of 0.84 and a current ratio of 0.84. The stock has a fifty day moving average price of $150.79 and a 200-day moving average price of $180.93.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. grew its position in shares of IQVIA by 0.5% in the 4th quarter. Vanguard Group Inc. now owns 20,131,734 shares of the medical research company's stock worth $3,956,087,000 after buying an additional 105,504 shares during the period. Canada Pension Plan Investment Board boosted its stake in IQVIA by 7.3% in the 1st quarter. Canada Pension Plan Investment Board now owns 4,594,831 shares of the medical research company's stock worth $810,069,000 after purchasing an additional 312,807 shares in the last quarter. Geode Capital Management LLC boosted its stake in IQVIA by 1.9% in the 4th quarter. Geode Capital Management LLC now owns 4,175,524 shares of the medical research company's stock worth $818,315,000 after purchasing an additional 77,981 shares in the last quarter. Invesco Ltd. boosted its stake in IQVIA by 53.4% in the 4th quarter. Invesco Ltd. now owns 2,590,260 shares of the medical research company's stock worth $509,012,000 after purchasing an additional 902,226 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its stake in IQVIA by 45.7% in the 1st quarter. JPMorgan Chase & Co. now owns 2,545,014 shares of the medical research company's stock worth $448,686,000 after purchasing an additional 798,534 shares in the last quarter. 89.62% of the stock is currently owned by institutional investors.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.